Multi-Drug Rapid Test Cassette (Salivatracer) (Oral Fluid) Package Insert English

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human saliva. For healthcare professionals, including staff in healthcare facilities. Immunoassay for in vitro diagnostic use only

[INTENDED USE]

The Multi-Drug Rapid Test Cassette is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in saliva at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
6-Monoacetylmorphine(6-MAM)	6-Monoacetylmorphine	3/5/10
Amphetamine (AMP)	d-Amphetamine	25/50
Barbiturates (BAR)	Secobarbital	50
Buprenorphine (BUP)	Buprenorphine	5/10
Benzodiazepines (BZO)	Oxazepam	10/20
Cocaine (COC)	Benzoylecgonine	10/20/50
Cotinine (COT)	Cotinine	30/50
Fentanyl (FYL)	Fentanyl	10
Synthetic Marijuana (K2)	JWH-018 5-Pentanoic acid metabolite	25/30
AB-Pinaca (K2+)	AB-PINACA pentanoic acid metabolite	10
Ketamine (KET)	Ketamine	30/50
Methylenedioxymethamphetamine (MDMA)	d,I-Methylenedioxymethamphetamine	50
Methamphetamine (MET)	d-Methamphetamine	25/50
Methadone (MTD)	Methadone	30
Opiates (OPI/MOP)	Morphine	10/30/40/50
Oxycodone (OXY)	Oxycodone	20/40
Phencyclidine (PCP)	Phencyclidine	10
Propoxyphene (PPX)	d-Propoxyphene	30/50
Marijuana (THC)	A9-THC	15/40
Marijuana (THC)	11-or-9-THC-9∆ COOH	12/50
Tramadol (TML)	Cis-Tramadol	30/50
Zopiclone (ZOP)	Zopiclone	20

This assay provides only a preliminary analytical test result. A more specific alternate chemical method should be used to confirm a preliminary positive analytical result. Gas chromatography/mass spectrometry (GC/MS), gas chromatography/tandem mass spectrometry (GC/MS/MS), liquid chromatography/mass spectrometry (LC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS/MS) are the preferred confirmatory methods. Professional judgment should be applied to any drug of abuse screen test result, particularly when preliminary positive results are indicated.

[SUMMARY]

The Multi-Drug Rapid Test Cassette is a rapid saliva screening test that can be performed without the use of an instrument. The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in human saliva.

6-MonoacetvImorphine(6-MAM)

6-Monoacetylmorphine (6-MAM) or 6-Acetylmorphine (6-AM) is one of three active metabolites of heroin (diacetylmorphine), the others being morphine and the much less active3-Monoacetylmorphine (3-MAM). 6-MAM occurs as a metabolite of heroin, which is rapidly created from heroin in the body. Heroin is rapidly metabolized by esterase enzymes in the brain and has an extremely short half-life. It has also relatively weak affinity to µ-opioid receptors because the 3-hydroxy group, essential for effective binding to the receptor, is masked by the acetyl group. Therefore, heroin acts as a pro-drug, serving as a lipophilic transporter for the systemic delivery of morphine, which actively binds with u-opioid receptors

Amphetamine (AMP)

Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self-administered by nasal inhalation or oral ingestion. Depending on the route of administration, amphetamine can be detected in oral fluid as early as 5-10 minutes following use¹. Amphetamine can be detected in oral fluids for up to 72 hours after use¹

Barbiturates (BAR)

Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of intoxication with alcohol. Chronic use of Barbiturates leads to tolerance and physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

Buprenorphine(BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is soldunder the trade names Subutex™, Buprenex™, Temgesic™, and Suboxone™ which contain Buprenorphine HCI alone or in combination with Naloxone HCI. Therapeutically, Buprenorphine is usedas a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence.

Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation routes

Benzodiazepines (BZO)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines have replaced Barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure

disorders and alcohol withdrawal. Risk of physical dependence increases if Benzodiazepines are taken regularly (e.g., daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can bring on such symptoms as trouble sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Cocaine (COC)

Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic derived from the coca plant (erythroxylum coca). The drug is often self-administered by nasal inhalation, intravenous injection and free-base smoking. Depending on the route of administration, cocaine and metabolites benzoylecgonine and ecgonine methyl ester can be detected in oral fluid as early as 5-10 minutes following use1. Cocaine and benzoylecgonine can be detected in oral fluids for up to 24 hours after use¹

Cotinine (COT)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays.

Although nicotine is excreted in saliva, the relatively short half-life of the drug makes it an unreliable maker for tobacco use. Cotinine, however, demonstrates a substantially longer half-life than nicotine bears a high correlation with plasma cotinine levels and has been found to be the best maker for smoking status compared with saliva nicotine measurement, breath carbon monoxide testing and plasma thiocyanate testing. The window of detection for cotinine in saliva at a cutoff level of 30 ng/mL is expected to be up to 1-2 days after nicotine use.

Fentanyl (FYL)

Fentanyl, belongs to powerful narcotics analgesics, and is a µ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations "Single Convention of narcotic drug in 1961". Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc, which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose.

Synthetic Marijuana (K2)

Synthetic Marijuana or K2 is a psychoactive herbal and chemical product that, when consumed, mimics the effects of Marijuana. It is best known by the brand names K2 and Spice both of which have largely become genericized trademarks used to refer to any synthetic Marijuana product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and also may have the ability to trigger a chronic (long-term) psychotic disorder among vulnerable individuals such as those with a family history of mental illness.

As of March 1, 2011, five cannabinoids, JWH -018, JWH- 073, CP- 47, JWH- 200 and cannabicyclohexanol are now illegal in the US because these substances have the potential to be extremely harmful and, therefore, pose an imminent hazard to the public safety. AB-Pinaca (K2+)

Synthetic cannabinoids are designer drugs that are structurally different from THC (the active component of cannabis) but act in similar ways to affect the cannabinoid receptor system in thebrain. Over the past few years, this class of designer drugs has mainstreamed to become globally popular and increasingly problematic. Synthetic cannabinoids fall into seven major structural groups:

- 1 .Naphthoylindoles (e.g. JWH-018, JWH-073)
- 2. Naphthylmethylindoles (JWH-175, JWH-184, JWH-185, JWH-199) 3 .Naphthovlpyrroles (JWH-145, JWH-146, JWH-147, etc)
- 4. Naphthylmethylindenes (JWH-176)
- 5. Phenylacetylindoles (JWH-250, JWH-251, JWH-302)
- 6. Cyclohexylphenols (e.g. CP 47,497)

7. Dibenzopyrans (classic cannabinoid structure such as. HU-210 and HU-211) New structural group: Aminoalkylindazoles (AB-PINACA, AB-FUBINACA, AB-CHMINACA, etc)

In their original, chemical state, synthetic cannabinoids are liquid. The drugs are usually sold combined with dried herbs that emulate marijuana and are intended for smoking although powdered versions are also available. As laws are written to control these drugs with each new synthetic cannabinoid class as they are introduced to the market, the older versions (JWH-018,JWH-073) are seen less frequently than years past. The current trend shows the aminoalkylindazole based drugs such as AB-PINACA, AB-FUBINACA and AB-CHMINACA

Ketamine (KET)

Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blockedspeech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function butnot of the central nervous system, and cardiovascular function is maintained. The effects of Ketamine generally last 4-6 hours following use

Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug (Nichols and Oberlender, 1990). The most pervasive effect of MDMA, occurring in virtually all people who took a reasonable dose of the drug, was to produce a clenching of the jaws

Methamphetamine (MET)

Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral ingestion. Depending on the route of administration, methamphetamine can be detected in oral fluid as early as 5-10 minutes following use¹. Methamphetamine can be detected in oral fluids for up to 72 hours after use1

Methadone (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine).

Methadone is a long acting pain reliever producing effects that last from twelve to forty-eight hours. Ideally, methadone frees the client from the pressures of obtaining illegal heroin, from the dangers of injection, and from the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists. **Opiates (OPI)**

The drug class opiates refers to any drug that is derived from the opium poppy, including naturally occurring compounds such as morphine and codeine and semi-synthetic drugs such as heroin. Opiates act to control pain by depressing the central nervous system. The drugs demonstrate addictive properties when used for sustained periods of time; symptoms of withdrawal may include sweating, shaking, nausea and irritability. Opiates can be taken orally or by injection routes including intravenous, intramuscular and subcutaneous; illegal users may also take the intravenously or by nasal inhalation. Using an immunoassay cutoff level, codeine can be detected in the oral fluid within 1 hour following a single oral dose and can remain detectable for 7-21 hours after the dose³. Heroin metabolite 6-monoacetylmorphine (6-MAM) is found more prevalently in excreted unmetabolized, and is also the major metabolic product of codeine and heroin.

Oxycodone (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy.Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, Tylox®, Percodan® and Percocet®. While Tylox®, Percodan® and Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone

Phencyclidine (PCP)

Phencyclidine, the hallucinogen commonly referred to as Angel Dust, can be detected in saliva as a result of the exchange of the drug between the circulatory system and the oral cavity. In a paired serum and saliva sample collection of 100 patients in an Emergency Department, PCP was detected in the saliva of 79 patients at levels as low as 2 ng/mL and as high as 600 ng/mL⁴.

Propoxyphene (PPX)

Propoxyphene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet[™], one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of proposyphene are achieved from 1 to 2 hours post dose. In the case of overdose, proposyphene blood concentrations can reach significantly higher levels. In humans, propoxyphene is metabolized by N-demethylation to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30 to 36 hours) than parent propoxyphene (6 to 12 hours). The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant toxicity

Marijuana (THC)

THC (A9-tetrahydrocannabinol) is the primary active ingredient in cannabis (marijuana). When smoked or orally administered. THC produces euphoric effects, Users have impaired short term memory and slow learning. They may also experience transient episodes of confusion and anxiety. Long-term, relatively heavy use may be associated with behavioral disorders.

The parent THC also known as ∆9-THC is present in oral fluid after use.

The detection of the drug is thought to be primarily due to the direct exposure of the drug to the mouth (oral and smoking administrations) and thesubsequent sequestering of the drug in the buccal cavity⁵ Historical studies have shown a window of detection for THC in saliva of up to 14 hours after drug use⁵. Tramadol(TML/TRA)

Tramadol (TML) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Largedoses of tramadol can develop tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. The majorpathways appear to be N- and Odemethylation, glucoronidation or sulfation in the liver.

Zopiclone (ZOP)

Zopiclone is a non-benzodiazepine hypnotic (classified as a cyclopyrrolone) used in the treatment of insomnia. It is rapidly absorbed after oral administration, reaching its maximum concentration in plasma 1-1.5 hours later, the oral bioavailability is close to 80%.45%-80% of zopiclone binds to plasma protein and is widely distributed throughout the body. Its concentration in saliva is higher than in plasma. The bitter taste is proportional to the concentration in saliva. Since zopiclone was used in clinic in 1985, its abuse and dependence tendency has been a controversial topic. Some studies have pointed out that the risk is low or small, but at the same time, in different countries, there are more and more individual reports of abuse, dependence and withdrawal complications.

ASSAY PRINCIPLE

The Multi-Drug Rapid Test Cassette is an immunoassay based on the principle of competitive binding. Drugs that may be present in the oral fluid specimen compete against their respective drug conjugate for binding sites on their specific antibody

During testing, a portion of the oral fluid specimen migrates upward by capillary action. A drug, if present in the oral fluid specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration in the oral fluid specimen will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region.

A drug-positive oral fluid specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative oral fluid specimen will generate a line in the test line region because of the absence of drug competition.

To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred [REAGENTS]

Each test line contains anti-drug antibody and corresponding drug-protein conjugates. The control line contains goat anti-rabbit IgG polyclonal antibodies and rabbit IgG.

[PRECAUTIONS]

- Do not use after the expiration date
- The test should remain in the sealed pouch until use.
- Saliva is not classified as biological hazard unless derived from a dental procedure.
 The used collector and cassette should be discarded according to federal, state and local

regulations.

[STORAGE AND STABILITY]

Store as packaged in the sealed pouch at 2-30°C. The test is stable through the expiration date printed on the sealed pouch. The test cassettes must remain in the sealed pouch until use. DO NOT FREEZE. Do not use heavond the expiration date.

[SPECIMEN COLLECTION AND PREPARATION]

The oral fluid specimen should be collected using the collector provided with the kit. Follow the detailed Directions for Use below. No other collection cassettes should be used with this assay. Oral fluid collected at any time of the day may be used.

• Test cassettes

I	Mat	erials	Provided	ł

Package insert
 Procedure Card(when applicable)
Materials Required but Not Provided


Timer [DIRECTIONS FOR USE]

Allow the test cassette, specimen, and/or controls to reach room temperature (15-30°C) prior to testing. Instruct the donor to not place anything in the mouth including food, drink, gum or tobacco products for at least 10 minutes prior to collection.

- Bring the pouch to room temperature before opening. Remove the test from the sealed pouch and use within one hour of opening.
- Instruct the donor to place the tongue against the root of the upper or lower jaw and collect saliva in the mouth.
- 3. Remove the swab from the cassette, then remove the cap from the swab.
- Instruct the donor to place the swab between the lower cheek and gum and gently rub back and forth between the left and right cheeks and gums until the sponge is completely saturated with saliva. Do not bite, suck, or chew the sponge as it may break.
- 5. Remove the swab when two red/pink lines appear on the back of the swab or when the red/pink lines form a 3/4 turn, insert the swab into the cassette. If the saturation indicator has not turned red, place the swab back in the mouth and continue to collect saliva until the saturation indicator turns red. Note: When inserting the swab into the cassette, insert the protruding part of the swab head into the hole reserved at the sampling site, and then press down the tail of the swab to secure it.

6. Move the slider in the direction of the arrow until the slider is blocked.

7. Place the device on a flat surface while the test is running. Negative results can be read as soon as clear lines form in both the C and T zones of the test. Read presumptive positive results at 10 minutes. Do not read results after 20 minutes.



[INTERPRETATION OF RESULTS]

(Please refer to the previous illustration)

NEGATIVE*: Two lines appear. One colored line should be in the control region (C), and another apparent colored line adjacent should be in the test region (Drug/T). This negative result indicates that the drug concentration is below the detectable level.

*NOTE: The shade of color in the test line region (Drug/T) will vary, but it should be considered negative whenever there is even a faint line.

POSITIVE: One colored line appears in the control region (C). No line appears in the test region (Drug/T). This positive result indicates that the drug concentration is above the detectable level.

INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test panel. If the problem persists, discontinue using the lot immediately and contact the manufacturer.

[QUALITY CONTROL]

A procedural control is included in the test. A colored line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

[LIMITATIONS]

- The Multi-Drug Rapid Test Cassette provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS), gas chromatography/tandem mass spectrometry (GC/MS/MS), liquid chromatography/mass spectrometry (LC/MS) or liquid chromatography/tandem mass spectrometry (LC/MS/MS) are the preferred confirmatory methods.
- A positive test result does not indicate the concentration of drug in the specimen or the route of administration.

A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the specimen below the cutoff level of the assay.

Accuracy

[PERFORMANCE CHARACTERISTICS]

Assemble each single test into the cassette before testing, and evaluate the cassette with approximately 44-280 specimens per drug type previously collected from subjects presenting for Drug Screen Testing which were confirmed by GC/MS. These specimens were randomized and tested using the Oral Fluid Drug Screen Test. Specimens were rated as either positive or negative at 10 minutes. The test results are shown in table below.

Table: Specimen Correlation

GC/MS Method % Total % agreement agreement with with GC/MS GC/MS Positive Multi-Drug Screen Tes Negative 36 >99% Positive 0 6-MAM 3 >99% Negative 0 128 >99% 36 0 >99% Positive 6-MAM 5 >99% 128 >99% Negative 0 36 >99% 6-MAM Positive 0 >99,0 % 10 Negative 0 128 >99% Positive 56 2 96.6% AMP 25 97.5% Negative 2 100 98.0% Positive 90 6 94,7 % AMP50 94.8% Negative 5 109 94.8% Positive 80 6 96.4% BAR50 95.7% 121 95.3% Negative 3 Positive 86 5 95.6% BUP5 95.7% 4 115 95.8% Negative 86 5 95.6% Positive BUP10 95.7% Negative 4 115 95.8% Positive 94 5 94.0% **BZO10** 94.8% Negative 6 105 95.5% 94 94.0% Positive 5 **BZO20** 94.8% Negative 6 105 95.5% 37 Positive 3 90.2% COC10 95.3% Negative 4 106 97.2% Positive 38 2 95.0% COC20 96.7% 107 97.3% Negative 3 38 95.0% Positive 2 COC50 96 7% 107 97.3% Negative 3 Positive 131 2 99.2% COT30 98.7% Negative 96 98.0% 131 Positive 2 99.2% COT 50 98 7% Negative 96 98.0% 53 98.1% Positive 1 FYL10 96.7% Negative 4 92 95.8% K2 52 2 Positive 96.3% (SMA) 96.0% Negative 4 92 95.8% 25 K2 Positive 52 2 96.3% (SMA) 96.0% Negative 4 92 95.8% 30 4 >99% Positive 0 K2+10 >99.0% Negative 0 40 >99% 49 Positive 3 94.2% KET 30 94.5% Negative 5 88 94.6% Positive 90 6 93.8% KET 50 94.8% Negative 5 109 95.6% Positive 96 97.0 % MDMA50 98.3% Negative 3 130 99.2% Positive 43 2 95.6% MET 25 96.4% 96.8% Negative 3 92 126 4 99.2% Positive MET 50 98.2% 149 97.4% Negative 1 Positive 116 3 97.5% MTD 30 97.4% Negative 3 108 97.3% Positive 88 8 92.6% **OPI 10** 92.9% Negative 7 107 93.0% Positive 61 3 95.3% **OPI 30** 96.8% 2 89 97.8% Negative Positive 89 7 93,7 % **OPI 40** 93.8% Negative 6 108 93.9% Positive 89 7 93,7 % **OPI 50** 93.8% 108 93.9% Negative 6 OXY 20 Positive 91 97.8% 98.7%

	Negative	2	136	99.3%			
OXY 40	Positive	93	0	>99%	>99%		
0/1 40	Negative	0	137	>99%	>99%		
PCP 10	Positive	107	2	96.4%	97.4%		
PCP IU	Negative	4	117	98.3%	97.4%		
PPX 30	Positive	92	3	95.8%	96.7%		
PPX 30	Negative	4	111	97.4%	90.7%		
PPX 50	Positive	Positive 92 3		Positive 92 3 95.8%		95.8%	96.7%
PPX 50	Negative	4	111	97.4%	96.7%		
TUO 45	Positive		0	95.6%	07.00/		
THC 15	Negative	2	45	99%	97.8%		
TUO 10	Positive	45	0	95.7%	00.00/		
THC 40	Negative	2	52	>99%	98.0%		
TUOIO	Positive	75	5	96.2%	00.00/		
THC12	Negative	3	167	97,1 %	96.8%		
TUO 50	Positive	75	5	96.2%	00.00/		
THC 50	Negative	3	167	97,1 %	96.8%		
TML/TRA	Positive	89	0	>99%	000/		
30	Negative	0	121	>99%	>99%		
TML/TRA	Positive	80	6	93.0%			
50	Negative	3	121	97.6%	95.7%		
	Positive	36	0	>99%			
ZOP 20	Negative	0	114	>99%	>99%		
Phosphate-	- buffered saline (tical Sensitivit	ty drugs to target con	centrations of + 5		

A Phosphate-buffered saline (PBS) pool was spiked with drugs to target concentrations of \pm 50% cut-off, \pm 25% cut-off and +300% cut-off and tested with the Multi-Drug Rapid Test Cassette. The results are summarized below.

Drug conc.	-	AM	P50	ME	T50	TH	IC15	TH	C40
(Cut-off range)	n	-	+		+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	27	3	28	2	27	3	26	4
Cut-off	30	15	15	16	14	12	18	12	18
+25% Cut-off	30	7	23	6	24	5	25	5	25
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30
									T F0
Drug conc.	n	PC			020		PI40		T50
(Cut-off range) 0% Cut-off	20	-	+	-	+	-	+	-	+
-50% Cut-off	30 30	30 30	0	30 30	0	30 30	0	30 30	0
-25% Cut-off	30	25	5	26	4	27	3	25	5
Cut-off	30	25 14	5 16	14	4	13	3	18	12
+25% Cut-off	30	14	20	5	25	7	23	8	22
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30
+300 % Cut-On	30	0	30	0	30	0	30	0	30
Drug conc.		MT	D30	ox	Y20	CC	OT30	MD	/A50
(Cut-off range)	n	-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	25	5	27	3	25	5	26	4
Cut-off	30	15	15	20	10	20	10	19	11
+25% Cut-off	30	7	23	4	26	7	23	6	24
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30
	1								
Drug conc.	n	BA		COC	20	KE	T30	BU	P10
(Cut-off range)		-	+	-	-	-	+	-	+
0% Cut-off	30	30	0	30	30	30	0	30	0
-50% Cut-off -25% Cut-off	30 30	30 23	0	30 25	0 5	30 25	0	30 27	0
Cut-off	30	23 16	14	25 15	5 15	16	5 14	15	15
+25% Cut-off	30	6	24	3	27	4	26	7	23
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30
1000/0 041 011	00	v	00	ů	00	Ű	00	ů	00
Drug conc.		6-M/	M10	TML/	TRA30	FY	/L10	K2	25
(Cut-off range)	n	-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	27	3	25	5	24	6	26	4
Cut-off	30	14	16	14	16	15	15	15	15
+25% Cut-off	30	4	26	4	26	3	27	4	26

+ 300% Cut-off 30 0 30	+50% Cut-off	30	0	30	0	30	0	30	0	30
(Cut-off range) n - +						-	-			30
(Cut-off range) n - +			140	40					-	0.54
0* Cut-off 30 0 30 0 30 0 30 0 30 0 25% Cut-off 30 15		n	K2-		- B(BZ			
56% Cut-off 30 0 30 0 30 0 30 0 30 0 25% Cut-off 30 15		30	30		30		30		30	
Cut-off 30 15 16 14 17 17 123 15 15 15 <						-				0
•25% Cut-off 30 3 27 7 23 7 23 3 2 •50% Cut-off 30 0 30	-25% Cut-off	30	27	3	27	3	27	3	25	5
+50% Cut-off 30 0 30 </td <td>Cut-off</td> <td>30</td> <td></td> <td>15</td> <td>15</td> <td>15</td> <td>15</td> <td>15</td> <td>15</td> <td>15</td>	Cut-off	30		15	15	15	15	15	15	15
+300% Cut-off 30 0 30<										27
Drug conc. (Cut-off range) n OPISO - COC10 + OPHO + - + + - + + <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>30</td>		-								30
(Cut-off range) n - + +	+300 % Cut-011	30	0	30	0	30	0	30	0	30
(cut-off ange) n + - + 15 15 15 15 15 15 13 13 11 125 15 13 13 11 125 13 13 11 14 <t< td=""><td>Drug conc.</td><td></td><td>OP</td><td>150</td><td>OX</td><td>Y40</td><td>CO</td><td>C10</td><td>OP</td><td>110</td></t<>	Drug conc.		OP	150	OX	Y40	CO	C10	OP	110
-50% Cut-off 30 30 0 30 0 30 0 30 0 30 0 -25% Cut-off 30 15 16 14 14 16 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 15 15 15 15 15		n	-	+	•	+	-	+	-	+
-25% Cut-off 30 27 3 25 5 26 4 26 4 Cut-off 30 15 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 14 14 16 16 12										
Cut-off 30 15 15 15 15 15 15 15 13 11 +25% Cut-off 30 0		-								
+25% Cut-off 30 8 22 7 23 3 27 7 23 +300% Cut-off 30 0 30										17
+300% Cut-off 30 0 30<										23
Drug conc. (Cut-off range) n AMP25 COT50 MET25 OPI30 9% Cut-off 30 30 0 30	+50% Cut-off	30	0	30	0	30	0	30	0	30
(Cut-off range) n - + + - + - + - + - + - + 0% Cut-off 30	+300% Cut-off	30	0	30	0	30	0	30	0	30
(Cut-off range) n - + + - + - + - + - + - + 0% Cut-off 30	Drug conc	T	ΔM	P25	00	T50	ME	T25	08	130
0% Cut-off 30 30 0 <td></td> <td>n</td> <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td>+</td>		n		-					-	+
-25% Cut-off 30 25 5 28 2 24 6 24 6 Cut-off 30 15 15 16 14 14 16 14 14 +25% cut-off 30 4 26 6 24 4 26 4 26 4 26 4 26 4 22 4 6 7 4 26 4 26 4 26 4 26 4 26 4 26 4 26 4 27 3 0 30 0 <td></td> <td>30</td> <td>30</td> <td></td> <td>30</td> <td></td> <td>30</td> <td>0</td> <td>30</td> <td>0</td>		30	30		30		30	0	30	0
Cut-off 30 15 15 16 14 14 16 14 11 +25 % cut-off 30 0 30								-		0
+25 % cut-off 30 4 26 6 24 4 26 4 22 +50 % cut-off 30 0 30					-			-		6
+50 % cut-off 30 0			-	-	-			-		16
+300% Cut-off 30 0 30<				-	-			-		30
Drug conc. (Cut-off range) n THC12 THC50 PPX30 PPX50 0% Cut-off 30 30 0 30			-		-				-	30
Cut.off range) n - + + - + - + - + - + - + - + -										
0% Cut-off 30 30 0 <td>•</td> <td>n</td> <td>TH</td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	•	n	TH	1						
-50% Cut-off 30 30 30<		30	-			-				-
-25% Cut-off 30 26 4 27 3 25 5 25 5 Cut-off 30 12 18 12 18 15 15 15 11 +25 % cut-off 30 0 30 30 30 3				-		-				0
+25 % cut-off 30 8 22 5 25 4 26 4 24 +50 % cut-off 30 0 30 30 30 30 30 30 30 30 30 30				-						5
+50 % cut-off 30 0 30 30 0 30 30 30 3	Cut-off	30	12	18	12	18	15	15	15	15
+300% Cut-off 30 0 30<										26
Drug conc. (Cut-off range) n 6-MAM 3 6-MAM 5 TML/TRA 50 SMA30 0% Cut-off 30 0 30 30 0 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>30</td></t<>										30
Cut-off range) n - + +	+300% Cut-On	30	0	30	0	30	0	30	0	30
(Cut-off range) - + 0 30 0 30 130 14 16 14 16 15 11 14 16 14 16 15 130 14 16 14 16 12 130 10 30 10 30 10 30 10 30 1	Drug conc.	n	6-M/	AM 3	6-M	AM 5	TML/1	RA 50	SM	A30
-50% Cut-off 30 30 30 10 30		_	-	+	-	+	-	+	-	-
-25% Cut-off 30 25 5 26 4 26 4 Cut-off 30 15 15 14 16 14 16 15 11 +25 % cut-off 30 4 26 14 16 1										0
Cut-off 30 15 15 14 16 14 16 15 15 +25 % cut-off 30 4 26 4 20 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 14 16 14 16 14 16 13 130 130 130 130 14 16 14 1										0 4
+25 % cut-off 30 4 26 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 0 30 26 4 26 4 26 4 26 4 26 4 26 4 26 4 26 30 30 30 30 30 30 30 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>15</td></t<>										15
+300% Cut-off 30 0 30	+25 % cut-off	30	4	26	4	26	4	26	4	26
Drug conc. (Cut-off range) n ZOP20 - + - + 0% Cut-off 30 30 0 -50% Cut-off 30 30 0 -25% Cut-off 30 26 4 Cut-off 30 14 16 +25 % cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 +so % cut-off 30 0 30 Fest Cassette identified positive results at a read time of 10 minutes. Compound ng/mL Compound ng/mL Compound ng/mL D-Amphetamine 250 (+)3.4.Methylenedioxyampheta mine 200 D,L-Amphetamine 35,000 250 mine (MDA) 25			-							30
n - + 0% Cut-off 30 30 0 -25% Cut-off 30 26 4 Cut-off 30 14 16 +25% Cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30	+300% Cut-off	30	0	30	Û	30	0	30	0	30
n - + 0% Cut-off 30 30 0 -25% Cut-off 30 26 4 Cut-off 30 14 16 +25% Cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30	Drug conc.	T	ZO	P20	1					
-50% Cut-off 30 30 0 -25% Cut-off 30 26 4 Cut-off 30 14 16 +25 % cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 rest Cassette identified positive results at a read time of 10 minutes. Compound ng/mL Compound ng/mL Compound ng/mL D-Amphetamine 25 p-Hydroxyamphetamine 200 D,L-Amphetamine 500 (+)3.4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHETAMINE (AMP50) 260		n	-	1	1					
-25% Cut-off 30 26 4 Cut-off 30 14 16 +25 % cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 Analytical Specificity The following table lists the concentration of compounds (ng/mL) above which the Multi-Drug F Compound ng/mL Compound ng/mL Compound ng/mL Compound ng/mL D-Amphetamine 25 p-Hydroxyamphetamine 200 D,L-Amphetamine 500 (+)3,4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHETAMINE (AMP50) 260										
Cut-off 30 14 16 +25 % cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 Float Analytical Specificity Fne following table lists the concentration of compounds (ng/mL) above which the Multi-Drug F Fest Cassette identified positive results at a read time of 10 minutes. Compound ng/mL Compound ng/mL Compound 10 P-Hydroxyamphetamine 200 D-Amphetamine 25 P-Hydroxyamphetamine 250 D,L-Amphetamine 500 (+)3,4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 4MPHETAMINE (AMP50) 4MPHETAMINE										
+25 % cut-off 30 4 26 +50 % cut-off 30 0 30 +300% Cut-off 30 0 30 +300% Cut-off 30 0 30 Flexible Analytical Specificity Specificity Flexible Compound (ng/mL) above which the Multi-Drug F Compound ng/mL Compound (ng/mL) AMPHETAMINE (AMP25) D D-Amphetamine 25 D,L-Amphetamine 500 L-Amphetamine 33,00 L-Amphetamine 30,00 AMPHETAMINE (AMP50)	0	20	4.4	4.0						
+50 % cut-off 30 0 30 +300% Cut-off 30 0 30 halytical Specificity State of 10 minutes. State of 10 minutes. Fest Cassette identified positive results at a read time of 10 minutes. Ing/mL Compound Compound ng/mL Compound Ing/mL D-Amphetamine 25 p-Hydroxyamphetamine 200 D,L-Amphetamine 500 (+)3.4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHETAMINE (AMP50) XMPHETAMINE (AMP50)					1					
Analytical Specificity Interfaction of compounds (ng/mL) above which the Multi-Drug F Fest Cassette identified positive results at a read time of 10 minutes. Compound ng/mL Compound ng/mL AMPHETAMINE (AMP25) D-Amphetamine 25 D,L-Amphetamine 500 L-Amphetamine 35,000 AMPHETAMINE (AMP50)			0		1					
Compound Ing/mL Compounds Ing/mL Compound Ing/mL Compound Ing/mL Compound Ing/mL Compound Ing/mL D-Amphetamine 25 p-Hydroxyamphetamine 200 D,L-Amphetamine 500 (+)3,4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHETAMINE (AMP50)	+300% Cut-off	30	0	30	l					
AMPHET AMINE (AMP25) D-Amphetamine 25 p-Hydroxyamphetamine 200 D,L-Amphetamine 500 (+)3,4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHET AMINE (AMP50) 250	est Cassette identified	the conce positive re	entration	of comp a read tin	ounds ne of 10	(ng/mL) a minutes.	above w	hich the		
D-Amphetamine 25 p-Hydroxyamphetamine 200 D,L-Amphetamine 500 (+)3,4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHETAMINE (AMP50)	Compound		AMP						ng/	mL
D,L-Amphetamine 500 (+)3,4-Methylenedioxyampheta mine (MDA) 250 L-Amphetamine 35,000 AMPHETAMINE (AMP50)	compound									
L-Amphetamine 35,000 AMPHETAMINE (AMP50)				25	p-H	/droxyam	nphetam	ine	200)
	D-Amphetamine				(+)3	,4-Methy			ta	
D-Amphetamine 50 ID-HV010XVambhetamine 1400	D-Amphetamine D,L-Amphetamine			500 35,000	(+)3 mine	,4-Methy e (MDA)			ta	

50

1,000

D-Amphetamine

D,L-Amphetamine

p-Hydroxyamphetamine (+)3,4-Methylenedioxyampheta mine (MDA)

400 500

25 30,000 200 12,500 750 25 100 19HETAMI 50 60,000 400 25,000 1,500 50 20,000 10 15 20,000 400 20,000 10 15 20,000 10 20,000 100 CAINE (C 20 CAINE (C 20 CAINE (C	11-nor -Δ9-THC-9 COOH (-) Δ8 -THC (+) Δ8 -THC THC40) 11-nor -Δ9-THC-9 COOH (-) Δ8 -THC (±) -11-Hydroxy-Δ9-THC (±) -11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11-nor -Δ9-THC-9 COOH Δ8-THC Δ8-THC Δ8-THC Δ8-THC Δ8-THC Δ8-THC Coton Δ8-THC Coton Coton Δ8-THC Coton Δ8-THC Coton Δ8-THC Coton Δ9-THC Coton	200 1,000 3,125 200 12,500 5,000 400 2,000 6,250 400 225,000 10,000 12.5 100 40 32 250 80 15 400 40 7.5 15
30,000 200 12,500 750 25 100 IPHETAMI 50 60,000 400 25,000 15 200 XUUANA (15 20,000 400 XUUANA (12 20,000 400 12 20,000 100 XUUANA (12 20,000 100 CAINE (C 20 CAINE (C CAINE (C	Procaine I-Phenylephrine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I-Methamphetamine I-Methamphetamine I-Phenylephrine I-Phenylephrine Ephedrine Benzphetamine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I1-nor -Δ9-THC-9 COOH (-) Δ8 -THC (+) Δ8 -THC I1-nor -Δ9-THC-9 COOH (-) Δ8 -THC I1-nor -Δ9-THC-9 COOH (-) Δ8 -THC I1-nor -Δ9-THC-9 COOH (+) Δ8 -THC I1-nor -Δ9-THC-9 COOH (±) Δ8 -THC ITHC12) Δ9-THC (±) Δ8 -THC I1-nor -Δ9-THC-9 COOH Δ9-THC (±) Δ8 -THC I1-nor -Δ9-THC-9 COOH Δ9-THC I2-01-40-70 COOH Δ9-THC I2-02-100	1,000 3,125 200 12,500 5,000 400 2,000 6,250 400 25,000 10,000 12,500 400 25,000 10,000 40 32 250 80 15 400 40 40 7.5
200 12, 500 750 25 100 PHETAMI 50 60,000 400 25,000 1,500 50 200 200 200 200 200 200 200 200 2	I-Phenylephrine (R)-(-)-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I-Nenylephrine (IR,2S) - (-) Ephedrine Procaine I-Phenylephrine (B)-(-)-Phenylephrine (B)-(-)-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (-) Δ8 -THC (+) Δ8 -THC (+) Δ8 -THC (+) Δ8 -THC (+) Δ8 -THC THC12) Δ9- THC (±) Δ8 -THC THC30 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC THC30 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC C(±) Δ8 -THC 2(±) Δ8 -THC DEC00 11- nor -Δ9-THC-9 COOH Δ8 -THC C0C10) EcgonineHCI Cocaethylene	3,125 200 12,500 5,000 6,250 400 25,000 10,000 12,55 100 40 32 250 80 15 400 40 40 300 100 7.5
12, 500 750 750 25 100 PHETAMI 50 60,000 400 25,000 1,500 50 200 200 200 20,000 400 20,000 10 20,000 10 20,000 100 CAINE (C 20 20 CAINE (C 20	(R)-(-)-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine NE (METS0) (1R,2S) - (-) Ephedrine Procaine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine 11- nor -Δ9-THC-9 COOH (+) Δ8 -THC YHC40) Δ9- THC (±) Δ8 -THC YHC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC YHC50 11- nor -Δ9-THC-9 COOH Δ8 -THC YHC50 11- nor -Δ9-THC-9 COOH Δ8 -THC YHC50 2) Δ8 -THC YHC50 <td< td=""><td>200 12, 500 5,000 400 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 32 250 80 15 400 40 7.5</td></td<>	200 12, 500 5,000 400 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 32 250 80 15 400 40 7.5
750 25 100 IPHETAMI 50 60,000 400 25,000 1,500 50 200 200 200 200 200 200 2	Benzphetamine L-Methamphetamine NE (MET50) (IR.2S) - (-) Ephedrine Procaine I-Phenylephrine (B)-(-) Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I-Neroylephrine (B)-(-) Phenylephrine Ephedrine Benzphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (-) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (-) Δ8 -THC THC412) Δ9- THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC 2(±) Δ8 -THC <td>12, 500 5,000 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 40 300 100 7.5</td>	12, 500 5,000 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 40 300 100 7.5
25 100 IPHETAMI 50 60,000 25,000 1,500 50 200 1,500 20,000 10 20,000 10 15 20,000 10 20,000 10 10 CAINE (C 20 20 CAINE (C 20 20 20 20 20 20 20 20 20 20 20 20 20	L-Methamphetamine NE (MET50) (1R,2S) - (-) Ephedrine Procaine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (+) Δ8 -THC (±) -11-Hydroxy-Δ9-THC (±) Δ8 -THC (±) Δ8 -T	5,000 400 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 32 250 80 15 400 40 7.5
100 IPHETAMI 50 60,000 400 25,000 1,500 50 200 10 20,000 400 20,000 10 20,000 10 CAINE (C 20 CAINE (C 20 CAINE (C	NE (MET50) (1R,2S) - (·) Ephedrine Procaine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I1- nor -Δ9-THC-9 COOH (·) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (·) Δ8 -THC THC12) Δ9- THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC THC50 11- nor -Δ9-THC-9 COOH Δ8 -THC OUD Δ9-THC 11- nor -Δ9-THC-9 COOH Δ8 -THC OUD Δ9-THC OUD Δ9-THC Δ9-THC Δ9-THC Δ9-THC COD 11- nor -Δ9-TH	400 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 40 300 100 7.5
100 IPHETAMI 50 60,000 400 25,000 1,500 50 200 10 20,000 400 20,000 10 20,000 10 CAINE (C 20 CAINE (C 20 CAINE (C	NE (MET50) (1R,2S) - (·) Ephedrine Procaine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine I1- nor -Δ9-THC-9 COOH (·) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (·) Δ8 -THC THC12) Δ9- THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC THC50 11- nor -Δ9-THC-9 COOH Δ8 -THC OUD Δ9-THC 11- nor -Δ9-THC-9 COOH Δ8 -THC OUD Δ9-THC OUD Δ9-THC Δ9-THC Δ9-THC Δ9-THC COD 11- nor -Δ9-TH	400 2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 40 300 100 7.5
IPHETAMI 50 60,000 400 25,000 1,500 50 200 1,500 50 20,000 400 20,000 10 10 CAINE (C 20 CAINE (C 20 CAINE (C 20 CAINE (C	((R,2S) - (-) Ephedrine Procaine Procaine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (-) Δ8 -THC (-) Δ9 -	2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 300 100 7.5
50 60,000 400 25,000 1,500 50 200 NJUANA (15 20,000 400 NJUANA (12 20,000 0 NJUANA (50 50,000 100 CAINE (C 20 CAINE (C	((R,2S) - (-) Ephedrine Procaine Procaine I-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (-) Δ8 -THC (-) Δ9 -	2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 300 100 7.5
60,000 400 25,000 1,500 50 200 200 200 200 20,000 400 400 40,000 800 20,000 12 20,000 10 50,000 100 CAINE (C 20 CAINE (C CAINE (C	Procaine I-Phenylephrine I-Phenylephrine Ephedrine Benzphetarmine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC DC00 EcgonineHCI Cocaethylene O2(20)	2,000 6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 300 100 7.5
400 25,000 1,500 50 200 20,000 400 400 400 40,000 800 20,000 100 20,000 100 CAINE (C 20 CAINE (C 20 CAINE (C	I-Phenylephrine (R)-(-)-Phenylephrine Ephedrine Benzphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (+) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (+) Δ8 -THC THC40 11- nor -Δ9-THC-9 COOH (+) Δ8 -THC (+) Δ8 -THC THC12) Δ9- THC (±) Δ8 -THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC THC50 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC Cocaethylene 0200)	6,250 400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 300 100 7.5
25,000 1,500 50 200 IJUUANA (15 20,000 400 400 400 20,000 800 IJUANA (12 20,000 100 CAINE (C 20 CAINE (C 20 CAINE (C CAINE (C CAINE (C	(R)-(·)-Prienylephrine Ephedrine Benzphetamine L-Methamphetamine 11- nor -Δ9-THC-9 COOH (·) Δ8 -THC (·) Δ8 -THC 11- nor -Δ9-THC-9 COOH (·) Δ8 -THC (·) Δ8 -THC (·) Δ8 -THC THC12) Δ9-THC (·) Δ8 -THC THC12) Δ9-THC (·) Δ8 -THC THC12) Δ9-THC (·) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC C010 EcgonineHCI Cocaethylene O20)	400 25,000 10,000 12.5 100 40 32 250 80 15 400 40 40 300 100 7.5
1,500 50 200 IJUUANA (15 20,000 400 400 400 40,000 800 IJUANA (12 20,000 100 CAINE (C 20 CAINE (C 20 CAINE (C CAINE (C	Ephedrine Benzphetamine L-Methamphetamine 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC (±) -11-Hydroxy-Δ9-THC (±) -11-Hydroxy-	25,000 10,000 12.5 100 40 32 250 80 15 400 40 300 100 7.5
1,500 50 200 IJUUANA (15 20,000 400 400 400 40,000 800 IJUANA (12 20,000 100 CAINE (C 20 CAINE (C 20 CAINE (C CAINE (C	Benzphetamine L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (+) Δ8 -THC (±) Δ8 -THC HC40) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC (±) -11-Hydroxy-Δ9-THC (±) -11-Hydroxy-Δ9-THC (±) -11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC Cocoethylene OC20) D	25,000 10,000 12.5 100 40 32 250 80 15 400 40 300 100 7.5
50 200 200 20,00	L-Methamphetamine THC15) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC COOH Δ8 -THC (±) Δ8 -THC COOH Δ8 -THC COOH COOH Coccaethylene COC0) COO	10,000 12.5 100 40 32 250 80 15 400 40 40 300 100 7.5
200 200 20,000 2	THC15) 11-пог -Δ9-THC-9 COOH (•) Δ8 -THC (•) Δ8 -THC THC40) 11-пог -Δ9-THC-9 COOH (•) Δ8 -THC (±) +11-Hydroxy-Δ9-THC (±) +11-Hydroxy-Δ9-THC-9 COOH Δ9-THC (±) +11-Hydroxy-Δ9-THC-9 COOH Δ8 -THC (±) +11-Hydroxy-Δ9-THC-9 COOH Δ8 -THC DOCIO EcgonineHCl Cocaethylene D200	12.5 100 40 32 250 80 15 400 40 40 300 100 7.5
RIJUANA (15 20,000 400 800 RIJUANA (40 40 800 RIJUANA (12 20,000 0 12 20,000 0 12 20,000 0 100 CAINE (C 10 CAINE (C 20 CAINE (C	11-nor -Δ9-THC-9 COOH (-) Δ8 -THC (+) Δ8 -THC THC40) 11-nor -Δ9-THC-9 COOH (+) Δ8 -THC (±) Δ8 -THC DECOD 20-THC (±) Δ8 -THC DECOD Cocaethylene OC20)	100 40 32 250 80 15 400 40 300 100 7.5
RIJUANA (15 20,000 400 800 RIJUANA (40 40 800 RIJUANA (12 20,000 0 12 20,000 0 12 20,000 0 100 CAINE (C 10 CAINE (C 20 CAINE (C	11-nor -Δ9-THC-9 COOH (-) Δ8 -THC (+) Δ8 -THC THC40) 11-nor -Δ9-THC-9 COOH (+) Δ8 -THC (±) Δ8 -THC DECOD 20-THC (±) Δ8 -THC DECOD Cocaethylene OC20)	100 40 32 250 80 15 400 40 300 100 7.5
15 20,000 400 RJUANA (40 40,000 RJUANA (12 20,00 100 RJUANA (50 50,000 100 CAINE (C 20 CAINE (C	11-nor -Δ9-THC-9 COOH (-) Δ8 -THC (+) Δ8 -THC THC40) 11-nor -Δ9-THC-9 COOH (+) Δ8 -THC (±) Δ8 -THC DECOD 20-THC (±) Δ8 -THC DECOD Cocaethylene OC20)	100 40 32 250 80 15 400 40 300 100 7.5
20,000 400 400 400 40,000 800 800 800 800 800 800 100 20,00 50,000 100 CAINE (C 20 20 20 CAINE (C CAINE (C	(-) Δ8 -THC (±) Δ8 -THC THC40) 11- nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC THC12) Δ9- THC (±) -11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC 2010) EcgonineHCl Cocaethylene 0200)	100 40 32 250 80 15 400 40 300 100 7.5
400 RJUANA (40 40,000 800 RJJUANA (12 20,00 0 10 RJUANA (50,000 1000 CAINE (C 20 CAINE (C CAINE (C	(±) Δ8 -THC THC40) 11 - nor -Δ9-THC-9 COOH (±) Δ8 -THC (±) Δ8 -THC (±) Δ8 -THC (±)-11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11 - nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC COCID) EcgonineHCl Cocaethylene OC20) OC20)	40 32 250 80 15 400 40 40 300 100 7.5
RIJUANA (40 40,000 800 RIJUANA (20,000 100 RUUANA (50 50,000 100 CAINE (C 10 10 10 CAINE (C 20 CAINE (C 20 CAINE (C	THC40) 11-nor -Δ9-THC-9 COOH (·) Δ8 -THC (±) Δ8 -THC (±) Δ8 -THC (±) -11-Hydroxy-Δ9-THC (±) -11-Hydroxy-Δ9-THC-9 COOH Δ8 -THC (±) -11-Hydroxy-Δ9-THC-9 COOH Δ8 -THC (±) -11-Hydroxy-Δ9-THC-9 COOH Δ8 -THC DC00 DC200	32 250 80 15 400 40 40 300 100 7.5
40 40,000 800 11 UUANA (12 20,00 0 100 100 100 CAINE (C 20 CAINE (C 20 CAINE (C	11- nor -Δ9-THC-9 COOH (-) Δ8 -THC (±) Δ8 -THC THC12) Δ9- THC (±)-11-Hydroxy-Δ9-THC	250 80 15 400 40 300 100 7.5
40,000 800 11 20,00 100 100 100 50,000 1000 CAINE (C 20 CAINE (C CAINE (C	(·) Δ8 -THC (±) Δ8 -THC THC 12) Δ9 - THC (±)-11-Hydroxy-Δ9-THC (±)-Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC (±) Δ8 -THC COC10) EcgonineHCl Coccaethylene OC20) OC20)	250 80 15 400 40 300 100 7.5
800 IJUANA (12 20,00 0 IJUANA (50 50,000 CAINE (C 20 CAINE (C 20 CAINE (C	(±) Δ8 -THC THC12) Δ9- THC (±)-11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC (±) Δ8 -THC COOH EcgonineHCl Coccaethylene OC20)	80 15 400 40 300 100 7.5
RIJUANA (12 20,00 0 100 RIJUANA (50,000 1000 CAINE (C 10 20 20 CAINE (C	THC12) Δ9- THC (±)-11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC OC10) EcgonineHCI Cocaethylene OC20)	15 400 40 300 100 7.5
12 20,00 0 100 100 50 50 50 50 50 CAINE (C 20 20 CAINE (C 20 CAINE (C	Δ9- THC (±)-11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC OC10) EggonineHCl Cocaethylene OC20)	400 40 300 100 7.5
20,00 0 100 20 20 20 20 20 20 20 0 20 0 20 0 20 2	(±)-11-Hydroxy-Δ9-THC (±) Δ8 -THC THC50 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC OC10 EcgonineHCl Cocaethylene OC20) OC20	400 40 300 100 7.5
0 100 20 20 20 100 100 10 10 10 10 10 10 20 20 CAINE (C	(±) Δ8 -THC THC50) 11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC OC10) EcgonineHCl Cocaethylene OC20) OC20)	40 40 300 100 7.5
100 RIJUANA (50 50,000 1000 CAINE (C 10 10 CAINE (C 20 20 CAINE (C	THC50) 11- nor -A9-THC-9 COOH A8 -THC (4) A8 -THC OC10) EcgonineHCl Cocaethylene OC20) OC20)	40 40 300 100 7.5
RIJUANA (50 50,000 1000 CAINE (C 10 10 CAINE (C 20 20 CAINE (C	THC50) 11- nor -A9-THC-9 COOH A8 -THC (4) A8 -THC OC10) EcgonineHCl Cocaethylene OC20) OC20)	40 300 100 7.5
50 50,000 1000 CAINE (C 10 10 CAINE (C 20 20 CAINE (C	11- nor -Δ9-THC-9 COOH Δ8 -THC (±) Δ8 -THC OC10) EcgonineHCl Cocaethylene OC20)	300 100 7.5
50,000 1000 CAINE (C 10 CAINE (C 20 20 CAINE (C	Δ8 -THC (±) Δ8 -THC OC10 EcgonineHCl Cocaethylene OC20	300 100 7.5
1000 CAINE (C 10 10 CAINE (C 20 20 CAINE (C	(±) ∆8 -THC OC10) EcgonineHCl Cocaethylene OC20)	100 7.5
CAINE (C 10 10 CAINE (C 20 20 CAINE (C	DC10) EcgonineHCl Cocaethylene DC20)	7.5
10 10 CAINE (C 20 20 CAINE (C	EcgonineHCl Cocaethylene OC20)	
10 CAINE (C 20 20 CAINE (C	Cocaethylene OC20)	
CAINE (C 20 20 CAINE (C	OC20)	15
20 20 CAINE (C		
20 CAINE (C	EUgunineriu	15
CAINE (C	Cocaethylene	30
		30
50	EcgonineHCl	37.5
50	Cocaethylene	75
PIATES (O		75
10	Morphine 3-β-D-Glucuronide	20
		-
5	Normorphine	10,000
25	Nalorphine	700
70	Oxymorphone	>10,000
270	Thebaine	>10,000
		25
		10
		30
		50
		50
		52,500
		75,000
		37,500
-		18,750
	DiacetyImorphine (Heroin)	40
	6-Monoacetylmorphine	100
	o-Acetyicodeine	90
	BI40)	I
		70
		70,000
		10,0000
		50,000
		25,000
		50
	o-wonoacety/morphine	125
		120
	6-Acetylcodeine	
PIATES (O	PI50)	
PIATES (O 50	PI50) Morphine 3-β-D-Glucuronide	90
PIATES (O	PI50)	
	1,000 ≥10,000 10,000 PIATES (O 30 40 40 150 75 600 45,00 0 PIATES (O 30,000 0 PIATES (O 50 50 50 200 100 800	1,000 DiacetyImorphine (Heroin) >10,000 6-MonoacetyImorphine 10,000 6-AcetyIcodeine PIATES (OPI30) 30 Morphine 3-β-D-Glucuronide 40 Normorphine 40 150 Oxymorphone 75 75 Thebaine 600 0 6-MonoacetyImorphine 0 30,00 6-AcetyIcodeine 0 9 Intestine 600 DiacetyImorphine (Heroin) 45,00 6-MonoacetyImorphine 0 9 Intestine 600 0 9 Intest (OPI40) 40 Morphine 3-β-D-Glucuronide 50 Nalorphine 3-β-D-Glucuronide 50 50 Nalorphine 3-β-D-Glucuronide 50 50 Nalorphine 3-β-D-Glucuronide 50 50 Nalorphine 3000 3-β-D-Glucuronide 50 Nalorphine 3000 3-β-D-Glucuronide 50 Nalorphine 3000 3-β-D-Glucuronide 50

Hydrocodone	150	Thebaine	35,000
Levorphanol	1,000	Diacetylmorphine (Heroin)	65
Oxycodone	75,000	6-Monoacetylmorphine	150
Dihydrocodeine	50,000	6-Acetylcodeine	150
	CYCLIDIN		
Phencyclidine	10 POXYPHEN	4-Hydroxyphencyclidine	2,500
D-Propoxyphene	30	D-Norpropoxyphene	30
	POXYPHEN		30
D-Propoxyphene	50	D-Norpropoxyphene	50
	QUALONE	(MQL100)	
Methaqualone	100		
	HADONE (000
Methadone Disopyramide	30 400	LAAM Doxylamine	200
(+)-Chlorpheniramine	6,250	Nor-LAAM	12,500 12,500
	CODONE (12,500
Oxycodone	20	Codeine	25,000
Oxymorphone	40	Dihydrocodeine	6,250
Levorphanol	10,000	Naloxone	5,000
Hydrocodone	1,500	Naltrexone	5,000
Hydromorphone	10,000	Thebaine	25,000
	CODONE		50.000
Oxycodone Oxymorphone	40 80	Codeine Dihydrocodeine	50,000 12,500
Levorphanol	20,000	Naloxone	10,000
Hydrocodone	3,000	Naltrexone	10,000
Hydromorphone	20,000	Thebaine	50,000
	OTININE (C		
(-)-Cotinine		(-)-Nicotine	450
			750
(-)-Cotinine	50	(-)-Nicotine PHETAMINE (MDMA50)	750
(±) 3,4-Methylenedioxymethamphetamine			50
(±) 3,4-Methylenedioxyamphetamine HCl (<i>(</i>)	300
3,4-Methylenedioxyethyl-amphetamine (MI			30
I-Methamphetamine			25,000
BENZO		ES (BZO20)	
Oxazepam	20	7-Amino-clonazepam	10,000
Alprazolam	200	Bromazepam	20
Chlordiazepoxide Desalkylflurazepam	100 1,000	Clonazepam	2,000 100
Estazolam	160	Diazepam Flunitrazepam	1,000
Furosemide	10,000	Lorazepam	1,400
Midazolam	2,000	Midazolam Maleate	5,000
Nefopam	2,000	Nitrazepam	50
Norchlordiazepoxide	50	Oxolinic acid	100,000
Pheniramine	100,000	Theophylline	100,000
α-Hydroxyalprazolam	100	50(D7040)	
	DIAZEPIN 10		E 000
Oxazepam Alprazolam	100	7-Amino-clonazepam Bromazepam	5,000 10
Chlordiazepoxide	50	Clonazepam	1,000
Desalkylflurazepam	500	Diazepam	50
Estazolam	80	Flunitrazepam	500
Furosemide	5,000	Lorazepam	700
Midazolam	1,000	Midazolam Maleate	2,500
Nefopam	1,000	Nitrazepam	25
Norchlordiazepoxide Pheniramine	25 50,000	Oxolinic acid Theophylline	50,000 50,000
a -Hydroxyalprazolam	50,000	пеорнушне	30,000
	ETAMINE(K	ET50)	
Ketamine (KET)	50	Norketamine	600
(+/-)-Chlorpheniramine	85,000	Pantoprazole Sodium	85,000
Levorphanol	85	hydromorphpne	4,000
Meperidine (Pethidine)	85,000	Promethazine	85,000
Naloxone	15,000	d-Pseudoephedrine	>100,000
Naltrexone EDDP	4,000	Phencyclidine	150
(2-ethylidene-1,5-dimethyl-3,3-diphenylp	8.500	Tetrahydrozoline	8,500
yrrolidine)	_,		.,
Normorphine	85,000	Heroin (diacetylmorphine)	85,000
Oxymorphone	1,500	Methamphetamine Hydrochride	85,000
Pheniramine	85,000	R(-)-Methamphetamine	85,000
		ET20)	
	ETAMINE(K		100
Ketamine (KET)	TAMINE(K 30	Norketamine	400
Ketamine (KET) (±)-Chlorpheniramine	30 50,000	Norketamine Pantoprazole Sodium	50,000
Ketamine (KET) (±)-Chlorpheniramine Levorphanol	TAMINE(K 30 50,000 50	Norketamine Pantoprazole Sodium hydromorphpne	50,000 2,500
Ketamine (KET) (±)-Chlorpheniramine Levorphanol Meperidine (Pethidine)	30 50,000 50 50,000	Norketamine Pantoprazole Sodium	50,000 2,500 50,000
Ketamine (KET) (±)-Chlorpheniramine Levorphanol	TAMINE(K 30 50,000 50	Norketamine Pantoprazole Sodium hydromorphpne Promethazine	50,000 2,500

EDDP		T () ()	
(2-ethylidene-1,5-dimethyl-3,3-diphenylpy rrolidine)	5,000	Tetrahydrozoline	5,000
Normorphine	50,000	Heroin (diacetylmorphine)	50,000
Oxymorphone	1,000	Methamphetamine	50,000
Pheniramine	50.000	Hydrochride R (-)-Methamphetamine	50,000
	BITURATES		00,000
Amobarbital	200	Pentobarbital	60
Aprobarbital	100	Phenobarbital	140
Butabarbital Butalbital	50 600	Secobarbital Primidone	50 95,000
Alphenal	200	Barbital	50
BUPF	RENORPHIN	IE(BUP5)	
Norbuprenorphine	90	Buprenorphine	5
Buprenorphine-3-β-D-glucuronide	50	Norbuprenorphine-3-β-D-glucu ronide	300
BUP	ENORPHIN		
Norbuprenorphine	180	Buprenorphine	10
		Norbuprenorphine-3-β-D-glucu	600
Buprenorphine-3-β-D-glucuronide	100	ronide	600
		PHINE(6-MAM3)	
6-Monoacetylmorphine	3	Diacetylmorphine (heroine)	10
		PHINE(6-MAM5)	45
6-Monoacetylmorphine	5	Diacetylmorphine (heroine)	15
6-Monoacetylmorphine		HINE(6-MAM10) Diacetylmorphine (heroine)	25
			20
Cis-tramadol	30	n-Desmethyl-cis-tramadol	15
Procyclidine	3,000	Phencyclidine	6,000
d,I-O-Desmethyl venlafaxine	15,000	o-Desmethyl-cis-tramadol	1,500
	MADOL(TMI	,	.,
Cis-tramadol	50	n-Desmethyl-cis-tramadol	25
Procyclidine	5,000	Phencyclidine	10,000
d,I-O-Desmethyl venlafaxine	25,000	o-Desmethyl-cis-tramadol	2,500
FI	ENTANYL(F	YL10)	
Fentanyl	10	Norfentanyl	4
Perphenazine	20,000		
SYNTHETIC	1	<u>, , , , , , , , , , , , , , , , , , , </u>	1
JWH-018 5-Pentanoic acid	25	MAM2201 N-Pentanoic acid	35
JWH-073 4-Butanoic acid	25	JWH-210 N-5-Carboxypentyl	210
JWH-018 4-Hydroxypentyl	210	JWH-398 N-Pentanoic acid	175 300
JWH-018 5-Hydroxypentyl JWH-073 4-Hydroxybutyl	300 170	JWH-200 6-Hydroxyindole JWH-073 N-2-Hydroxybutyl	300 500
JWH-018 N-Propanoic acid	20	JWH-019 5-Hydroxybexyl	500
JWH-019 6-Hydroxyhexyl	500	JWH-018	42,000
JWH-122 N-4-Hydroxypentyl	500	AM2201 N-(4-hydroxypentyl)	350
RCS4 N-5-Carboxypentyl	22,500	JWH-073 N-(3-hydroxybutyl)	225
		NA (K2 /SMA30)	
JWH-018 5-Pentanoic acid	30	MAM2201 N-Pentanoic acid	45
JWH-073 4-Butanoic acid	30	JWH-210 N-5-Carboxypentyl	300
JWH-018 4-Hydroxypentyl	300	JWH-398 N-Pentanoic acid	210
JWH-018 5-Hydroxypentyl	350	JWH-200 6-Hydroxyindole	360
JWH-073 4-Hydroxybutyl	200	JWH-073 N-2-Hydroxybutyl	600
JWH-018 N-Propanoic acid	25	JWH-019 5-Hydroxyhexyl	600
JWH-019 6-Hydroxyhexyl	600	JWH-018	50,000
JWH-122 N-4-Hydroxypentyl	600	AM2201 N-(4-hydroxypentyl)	420
RCS4 N-5-Carboxypentyl	27,000	JWH-073 N-(3-hydroxybutyl)	270
AI	3-Pinaca (K		
AB-PINACA pentanoic acid metabolite	10	AB-PINACA N-(4-hydroxypentyl) metabolite	10
ADB-PINACA N-(4-hydroxypentyl) metabolite	15	ADB-PINACA N-(5-hydroxypentyl) metabolite	20
5-fluoro AB-PINACA N-(4-hydroxypentyl)	20	ADB-PINACA pentanoic acid	20
AB-PINACA N-(5-hydroxypentyl)	30	5-fluoro AB-PINACA	50
metabolite AB-PINACA	30 100	AB-FUBINACA	150
5-fluoro ADB-PINACA	250	5-chloro AB-PINACA	1000
	PICLONE(Z		1000
	20		
Zopiclone			

A study was conducted to determine the cross-reactivity of the test with compounds spiked into drug-free PBS stock. The following compounds demonstrated no false positive results on the Multi-Drug Rapid Test Cassette when tested with at concentrations up to 10 ug/ml

Acetaminophen	Acetophenetidin	N-Acetylprocainamide
Acetylsalicylic acid	Aminopyrine	Amoxicillin
Ampicillin	I-Ascorbic acid	Aspartame
Atropine	Benzilic acid	Benzoic acid
d/l-Brompheniramine	Caffeine	Chloral-hydrate
Chloramphenicol	Chlorothiazide	Cortisone
Chlorpromazine	Chloroquine	Cholesterol
Creatinine	Deoxycorticosterone	Diclofenac
Diflunisal	Digoxin	Diphenhydramine
I(–)-Epinephrine	Erythromycin	β-Estradiol
Estrone-3-sulfate	Ethyl-p-aminobenzoate	Fenoprofen
Gentisic acid	Hydralazine	p-Hydroxytyramine
Hydrochlorothiazide	o-Hydroxyhippuric acid	Hydrocortisone
Ibuprofen	d/l-Isoproterenol	Isoxsuprine
Iproniazid	Ketoprofen	Labetalol
Loperamide	Meprobamate	Methylphenidate
Nalidixic acid	Naproxen	Niacinamide
Norethindrone	Nifedipine	d/I-Octopamine
Oxalic acid	Oxymetazoline	Penicillin-G
Papaverine	Phenelzine	Phenylpropanolamine
Trans-2-phenylcyclopropylamine hydrochloride	Prednisolone	Prednisone
d/I-Propranolol	d-Pseudoephedrine	Quinacrine
Quindine	Quinine	Ranitidine
Salicylic acid	Serotonin	Sulfamethazine
Sulindac	Tetracycline	Tetrahydrocortisone 3-acetate
Tetrahydrocortisone3-(β-D-glucu ronide)	Thiamine	Tolbutamide
Triamterene	Trifluoperazine	d/I-Tryptophan
Tyramine	d/I-Tyrosine	Uric acid
Verapamil	Zomepirac	

[BIBLIOGRAPHY]

Manufacturer

1. Moolchan, E., et al, "Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine", Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998.
Baselt RC. Disposition of Toxic Drugs and Chemicals in Man. 6th Ed. Biomedical Publ.,

Foster City, CA 2002.

3. Kim, I, et al, "Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration", ClinChem, 2002 Sept.; 48 (9), pp 1486-96.

4. McCarron, MM, et al, "Detection of Phencyclidine Usage by Radioimmunoassay of Saliva," J Anal Tox. 1984 Sep-Oct.; 8 (5), pp 197-201.

5. Schramm, W. et al, "Drugs of Abuse in Saliva: A Review," J Anal Tox, 1992 Jan-Feb; 16 (1), pp 1-9

		Index	of Symbols		
ī	Consult Instruction for use	Σ Σ	Tests per kit	EC REP	Authorized Representative within the European Community
IVD	For <i>in vitro</i> diagnostic use only	\square	Use by	2	Do not reuse
2°C - 30°C	Store between 2–30 °C	LOT	Lot Number	REF	Catalog Number
\$	Do not use if package is damaged	C€	CE Marking	***	Manufacturer
	Importer		Distributor	UDI	Unique Device Identification

Hangzhou Biotest Biotech Co., Ltd. 17#, Futai Road, Zhongtai Street, Yuhang District, Hangzhou, P. R. China C F

EC REP Shanghai International

Holding Corp. GmbH (Europe) Eiffestrasse 80, 20537 Hamburg, Germany



Importer and Distributor: Noviral S Imported by: Noviral Sweden AB. Importer and Distributor: Noviral Sweden AB.

Contact information : info@noviral.se +46 (0)10-880 08 47 Noviral Sweden AB Humlegårdsgatan 4, 3tr 114 46 Stockholm, Sweden

> RP5656900 Number: Effective date: 2025-04-30